Genomic Health, Inc. (Nasdaq:GHDX) announced that it has started a large clinical validation study of its prostate cancer test. The study, being performed in collaboration with leading prostate cancer researchers at the University of California, San Francisco (UCSF), is designed to determine if a multi-gene test can help distinguish aggressive disease requiring surgery from less aggressive disease that may undergo active surveillance in patients with early-stage prostate cancer. The study will utilize Genomic Health’s proprietary RT-PCR process for analyzing very small amounts of formalin-fixed paraffin-embedded (FFPE) prostate tissue obtained by needle biopsy prior to removal of the prostate. Complete results are expected to be presented at the end of this year or early next year, and if positive, are expected to support the launch of the Oncotype DX� prostate cancer test in 2013.
Genomic Health, Inc., a molecular diagnostics company, focuses on the development and global commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.
Cleantech Transit, Inc. (CLNO)
Cleantech Transit, Inc. is in the business of producing and conserving power. Cleantech Transit produces and sells clean electricity globally, with a focus on sustainable energies using renewable resources such as Geothermal, Solar and Wind. Cleantech Transit’s goal is to use innovative technologies to reduce electricity consumption and dependence on carbon based energy. Cleantech Transit, Inc. was founded in 2006 and is based in Scottsdale, Arizona.
Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company’s ability to earn in 25% of the 500KW Merced Project.
The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.
Biomass energy is an inexhaustible and renewable energy source. The products obtained are biogas and biofuel. Heat and electricity are generated during biomass energy production.
There is plethora of organic waste and agricultural waste generated everyday. Biomass is produced from these wastes, which makes biomass an easily available resource.
It helps in solid waste management by keeping us pollution free. Incineration of biological wastes everyday cuts down the levels of expulsion of carbon into the atmosphere. Thus, it maintains an ecological balance of carbon present in the environment.
Align Technology, Inc. (Nasdaq:ALGN) announced that the Company will report fourth quarter and fiscal year 2011 financial results on Monday, January 30, 2012 after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and will be available on the Investor Relations section of the Company’s website at http://investor.aligntech.com. Following the press release, the Company will host a conference call to discuss its financial results. The conference call will begin at 4:30 p.m. ET (1:30 p.m. PT) and will also be available as an audio web cast live via the Internet. To access the web cast, please visit http://investor.aligntech.com. To access the conference call, please dial 201-689-8261 approximately fifteen minutes prior to the start of the call.
Align Technology, Inc., together with its subsidiaries, engages in the design, manufacture, and marketing of the Invisalign system for treating malocclusion or the misalignment of teeth.
Ampio Pharmaceuticals, Inc. (Nasdaq:AMPE) a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced that CEO Don Wingerter would be granted a compassionate leave from all his duties at the company in order for him to attend to serious health problems afflicting both his parents. The term of leave is unknowable and should be considered indefinite at this time. Following Don’s extremely successful tenure as CEO will be Michael Macaluso , current Chairman of the Ampio Board of Directors and lead investor in DMI BioSciences, predecessor company to Ampio.
Ampio Pharmaceuticals, Inc., a development stage pharmaceutical company, together with its subsidiaries, engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction.
No comments:
Post a Comment